
Sean P. Gramling
Examiner (ID: 3948, Phone: (571)272-9082 , Office: P/2875 )
| Most Active Art Unit | 2875 |
| Art Unit(s) | 2809, 2112, 2875 |
| Total Applications | 1285 |
| Issued Applications | 833 |
| Pending Applications | 63 |
| Abandoned Applications | 412 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17312903
[patent_doc_number] => 20210401951
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-30
[patent_title] => MRNA THERAPY FOR POMPE DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/369783
[patent_app_country] => US
[patent_app_date] => 2021-07-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20323
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17369783
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/369783 | MRNA therapy for pompe disease | Jul 6, 2021 | Issued |
Array
(
[id] => 17505480
[patent_doc_number] => 20220098582
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-31
[patent_title] => Methods for Treatment of Alport Syndrome
[patent_app_type] => utility
[patent_app_number] => 17/366796
[patent_app_country] => US
[patent_app_date] => 2021-07-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17140
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17366796
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/366796 | Methods for Treatment of Alport Syndrome | Jul 1, 2021 | Abandoned |
Array
(
[id] => 17299909
[patent_doc_number] => 20210395748
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-23
[patent_title] => LOCALIZED THERAPY OF LOWER AIRWAYS INFLAMMATORY DISORDERS WITH PROINFLAMMATORY CYTOKINE INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/366835
[patent_app_country] => US
[patent_app_date] => 2021-07-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32202
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17366835
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/366835 | Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors | Jul 1, 2021 | Issued |
Array
(
[id] => 18825415
[patent_doc_number] => 11840686
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-12-12
[patent_title] => Modulation of prekallikrein (PKK) expression
[patent_app_type] => utility
[patent_app_number] => 17/367096
[patent_app_country] => US
[patent_app_date] => 2021-07-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 66203
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17367096
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/367096 | Modulation of prekallikrein (PKK) expression | Jul 1, 2021 | Issued |
Array
(
[id] => 18552429
[patent_doc_number] => 20230250438
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-10
[patent_title] => Blood-Brain Barrier Penetrating Aptamer and Use Thereof
[patent_app_type] => utility
[patent_app_number] => 18/013055
[patent_app_country] => US
[patent_app_date] => 2021-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9696
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18013055
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/013055 | Blood-Brain Barrier Penetrating Aptamer and Use Thereof | Jun 28, 2021 | Pending |
Array
(
[id] => 19931972
[patent_doc_number] => 12305171
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-20
[patent_title] => Compositions and methods for treating cancer
[patent_app_type] => utility
[patent_app_number] => 17/359905
[patent_app_country] => US
[patent_app_date] => 2021-06-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 55
[patent_no_of_words] => 23719
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 142
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17359905
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/359905 | Compositions and methods for treating cancer | Jun 27, 2021 | Issued |
Array
(
[id] => 17314871
[patent_doc_number] => 20210403919
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-30
[patent_title] => Aptamers For Personal Health Care Applications
[patent_app_type] => utility
[patent_app_number] => 17/356828
[patent_app_country] => US
[patent_app_date] => 2021-06-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23926
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 157
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17356828
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/356828 | Aptamers for personal health care applications | Jun 23, 2021 | Issued |
Array
(
[id] => 17608958
[patent_doc_number] => 20220151237
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-19
[patent_title] => INSECT CONTROL STRATEGIES UTILITIZING PHEROMONES AND RNAI
[patent_app_type] => utility
[patent_app_number] => 17/353559
[patent_app_country] => US
[patent_app_date] => 2021-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42905
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17353559
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/353559 | INSECT CONTROL STRATEGIES UTILITIZING PHEROMONES AND RNAI | Jun 20, 2021 | Abandoned |
Array
(
[id] => 19343661
[patent_doc_number] => 20240252624
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-01
[patent_title] => RECOMBINANT HVT VECTORS EXPRESSING INFLUENZA HEMAGGLUTININ AND IMMUNOGENIC COMPOSITIONS, AND PRODUCTION AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/000357
[patent_app_country] => US
[patent_app_date] => 2021-06-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43408
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -36
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18000357
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/000357 | RECOMBINANT HVT VECTORS EXPRESSING INFLUENZA HEMAGGLUTININ AND IMMUNOGENIC COMPOSITIONS, AND PRODUCTION AND USES THEREOF | Jun 15, 2021 | Pending |
Array
(
[id] => 17112166
[patent_doc_number] => 20210292763
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-23
[patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF COMPLICATIONS AND DISORDERS RELATING TO VON WILLEBRAND FACTOR
[patent_app_type] => utility
[patent_app_number] => 17/340824
[patent_app_country] => US
[patent_app_date] => 2021-06-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33153
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17340824
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/340824 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF COMPLICATIONS AND DISORDERS RELATING TO VON WILLEBRAND FACTOR | Jun 6, 2021 | Pending |
Array
(
[id] => 17110056
[patent_doc_number] => 20210290653
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-23
[patent_title] => MODULATION OF LNC05 EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 17/337762
[patent_app_country] => US
[patent_app_date] => 2021-06-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20641
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17337762
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/337762 | MODULATION OF LNC05 EXPRESSION | Jun 2, 2021 | Abandoned |
Array
(
[id] => 17546658
[patent_doc_number] => 20220117999
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-21
[patent_title] => PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/335125
[patent_app_country] => US
[patent_app_date] => 2021-06-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 64424
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17335125
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/335125 | PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | May 31, 2021 | Abandoned |
Array
(
[id] => 17096889
[patent_doc_number] => 20210284680
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-16
[patent_title] => ANTISENSE NUCLEIC ACIDS
[patent_app_type] => utility
[patent_app_number] => 17/333677
[patent_app_country] => US
[patent_app_date] => 2021-05-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16663
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17333677
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/333677 | ANTISENSE NUCLEIC ACIDS | May 27, 2021 | Abandoned |
Array
(
[id] => 20492860
[patent_doc_number] => 12534724
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-27
[patent_title] => Synthetic oligonucleotides having regions of block and cluster modifications
[patent_app_type] => utility
[patent_app_number] => 17/331146
[patent_app_country] => US
[patent_app_date] => 2021-05-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 36
[patent_no_of_words] => 49057
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 157
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17331146
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/331146 | Synthetic oligonucleotides having regions of block and cluster modifications | May 25, 2021 | Issued |
Array
(
[id] => 20453279
[patent_doc_number] => 12516331
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-06
[patent_title] => Monocyte-specific aptamers and uses thereof for enhancing drug delivery to cancer
[patent_app_type] => utility
[patent_app_number] => 17/927742
[patent_app_country] => US
[patent_app_date] => 2021-05-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 49
[patent_no_of_words] => 11737
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17927742
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/927742 | Monocyte-specific aptamers and uses thereof for enhancing drug delivery to cancer | May 25, 2021 | Issued |
Array
(
[id] => 18065708
[patent_doc_number] => 20220396795
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-15
[patent_title] => FUNCTIONAL LIGANDS TO SARS-COV-2 SPIKE PROTEIN
[patent_app_type] => utility
[patent_app_number] => 17/772128
[patent_app_country] => US
[patent_app_date] => 2021-05-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11855
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17772128
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/772128 | FUNCTIONAL LIGANDS TO SARS-COV-2 SPIKE PROTEIN | May 24, 2021 | Abandoned |
Array
(
[id] => 18448544
[patent_doc_number] => 20230189819
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => COMPOSITIONS AND METHODS FOR FUNGAL INHIBITION USING MINICELL-BASED RNAi
[patent_app_type] => utility
[patent_app_number] => 17/926069
[patent_app_country] => US
[patent_app_date] => 2021-05-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28537
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -55
[patent_words_short_claim] => 75
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17926069
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/926069 | COMPOSITIONS AND METHODS FOR FUNGAL INHIBITION USING MINICELL-BASED RNAi | May 18, 2021 | Pending |
Array
(
[id] => 18452006
[patent_doc_number] => 20230193285
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => BISPECIFIC PERSONALIZED APTAMERS
[patent_app_type] => utility
[patent_app_number] => 17/926067
[patent_app_country] => US
[patent_app_date] => 2021-05-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31623
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -154
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17926067
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/926067 | BISPECIFIC PERSONALIZED APTAMERS | May 18, 2021 | Pending |
Array
(
[id] => 18452007
[patent_doc_number] => 20230193286
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => CYTOTOXIC T-LYMPHOCYTE BINDING APTAMERS
[patent_app_type] => utility
[patent_app_number] => 17/926071
[patent_app_country] => US
[patent_app_date] => 2021-05-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18939
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -97
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17926071
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/926071 | CYTOTOXIC T-LYMPHOCYTE BINDING APTAMERS | May 18, 2021 | Pending |
Array
(
[id] => 17200444
[patent_doc_number] => 20210340539
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-04
[patent_title] => MODIFIED AAV CONSTRUCTS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/316769
[patent_app_country] => US
[patent_app_date] => 2021-05-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23619
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17316769
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/316769 | Modified AAV constructs and uses thereof | May 10, 2021 | Issued |